Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

NCT06353191 · View on ClinicalTrials.gov ↗

Study Summary

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Interventions

  • OTHER Non-Interventional Study

Study Locations (4)

Florida

  • Mayo Clinic in Florida — Jacksonville
  • Moffitt Cancer Center — Tampa

Arizona

  • Mayo Clinic in Arizona — Scottsdale

Minnesota

  • Mayo Clinic in Rochester — Rochester

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2019-05-03
Est. Completion 2031-12-31

Sponsor

Mayo Clinic

3,246 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06353191

The ClinicalTrials.gov registry entry for NCT06353191 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 3,246 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention — of which Non-Interventional Study is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06353191 reports 4 study locations spanning 3 distinct geographic areas — top geographies include Florida, Arizona, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06353191 about?

NCT06353191 is a clinical study titled "Biomarkers to Predict Cancer Therapy-related Cardiotoxicity". This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

What is the current status of trial NCT06353191?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-05-03. Estimated completion is 2031-12-31.

What conditions does trial NCT06353191 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06353191?

The interventions under investigation include: Non-Interventional Study (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06353191?

This trial is sponsored by Mayo Clinic, which has 3,246 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06353191 being conducted?

This trial has 4 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial